Active, not recruitingEarly Phase 1NCT06289452
Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
Studying X-linked retinoschisis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- InnoVec Biotherapeutics Inc.
- Intervention
- IVB102 Injection(genetic)
- Enrollment
- 18 target
- Eligibility
- 8 years · MALE
- Timeline
- 2024 – 2029
Study locations (1)
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Collaborators
Peking Union Medical College Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06289452 on ClinicalTrials.govOther trials for X-linked retinoschisis
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06345898Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)West China Hospital
- RECRUITINGPHASE1, PHASE2NCT05878860ATSN-201 Gene Therapy in RS1-Associated X-linked RetinoschisisAtsena Therapeutics Inc.
- RECRUITINGNANCT05814952Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine